Cetera Advisors’s Viridian Therapeutics VRDN Stock Holding History

Cetera Advisors’s Portfolio VRDN Stock Details VRDN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-19,945	Closed	-$507K	–	1771
2023 Q1	$507K	Buy	+19,945	New	+$640K	0.01%	1002

Other funds holding VRDN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

Cetera Advisors's VRDN Position: Q2 2023 in Review

Cetera Advisors sold out of Viridian Therapeutics (VRDN) in Q2 2023, closing a stake of 19,945 shares — an estimated $507K sold.

Cetera Advisors first reported a position in VRDN in Q1 2023 and held it in 1 quarter. The position peaked at $507K in Q1 2023. 128 funds tracked by Wall St. Rank hold VRDN as of Q2 2023.

Cetera Advisors reported no remaining Viridian Therapeutics position as of Q2 2023 after selling out during the quarter.
Cetera Advisors sold 19,945 Viridian Therapeutics shares in Q2 2023, an estimated $507K.
Cetera Advisors first reported a position in Viridian Therapeutics in Q1 2023 and held it in 1 quarter.
Cetera Advisors's Viridian Therapeutics position peaked at $507K in Q1 2023.
128 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q2 2023.

Based on Cetera Advisors's 13F filing for Q2 2023, filed 10 Aug 2023.